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Abstract
The precise contribution of astrocytes in neuroinﬂammatory process occurring in Parkinson’s disease (PD) is not well
characterized. In this study, using GRCx30CreERT2 mice that are conditionally inactivated for glucocorticoid receptor (GR) in
astrocytes, we have examined the actions of astrocytic GR during dopamine neuron (DN) degeneration triggered by the
neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The results show signiﬁcantly augmented DN loss in
GRCx30CreERT2 mutant mice in substantia nigra (SN) compared to controls. Hypertrophy of microglia but not of astrocytes
was greatly enhanced in SN of these astrocytic GR mutants intoxicated with MPTP, indicating heightened microglial
reactivity compared to similarly-treated control mice. In the SN of GR astrocyte mutants, speciﬁc inﬂammation-associated
transcripts ICAM-1, TNF-α and Il-1β as well as TNF-α protein levels were signiﬁcantly elevated after MPTP neurotoxicity
compared to controls. Interestingly, this paralleled increased connexin hemichannel activity and elevated intracellular
calcium levels in astrocytes examined in acute midbrain slices from control and mutant mice treated with MPP+ . The
increased connexin-43 hemichannel activity was found in vivo in MPTP-intoxicated mice. Importantly, treatment of MPTP-
injected GRCx30CreERT2 mutant mice with TAT-Gap19 peptide, a speciﬁc connexin-43 hemichannel blocker, reverted both
DN loss and microglial activation; in wild-type mice there was partial but signiﬁcant survival effect. In the SN of post-
mortem PD patients, a signiﬁcant decrease in the number of astrocytes expressing nuclear GR was observed, suggesting the
participation of astrocytic GR deregulation of inﬂammatory process in PD. Overall, these data provide mechanistic insights
into GR-modulated processes in vivo, speciﬁcally in astrocytes, that contribute to a pro-inﬂammatory state and dopamine
neurodegeneration in PD pathology.
Introduction
Reactive glial cells are key elements in the physiopathology
of Parkinson’s disease (PD) that is characterized by pro-
gressive degeneration of dopaminergic neurons (DNs) in the
substantia nigra (SN). This loss of DNs, along with a sig-
niﬁcant depletion of dopamine in nigrostriatal dopaminergic
terminals, is at the origin of cardinal motor symptoms of PD
including akinesia, tremor at rest and rigidity [1]. Although
both microglia and astrocytes play a role in neurodegen-
eration through secretion of potent inﬂammatory mediators
such as TNF-α or IL-1β, they most likely differ in their
contribution to PD pathology. Microglial activation in PD
patients is well documented by PET imaging and analysis of
post-mortem tissues [2, 3]. However, given the lack of PET
imaging markers speciﬁc for reactive astrocytes, post-
mortem studies of PD relying on immunohistochemical
analyses of astrocytes have yielded conﬂicting results. Thus,
GFAP labeling of astrocytes revealed either no change
[4, 5] or increased numbers GFAP-positive astrocytes [6] or
astrocyte hypertrophy [7]. Nevertheless, post-mortem stu-
dies indicate the involvement of astrocytes in PD pathology.
They revealed i) accumulation of α-synuclein in astrocytes
[8, 9] and its correlation with the extent of severity of nigral
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DN loss [10]; ii) fewer glutathione peroxidase (enzyme
involved in hydrogen peroxide scavenging) positive astro-
cytes in SN of PD patients [6]; iii) strong expression of I-
CAM and myeloperoxidase in astrocytes of SN [11] and
ﬁnally iv) increased S100β expression in astrocytes [12],
which may augment the immune responses through acti-
vation of RAGE and TNF-α receptors.
In pre-clinical models of PD, there is evidence of reactive
astrocytes participating in the pro-inﬂammatory responses
that lead to degeneration of DNs in SN [11, 13, 14]. The
astrocyte-speciﬁc mechanisms, which control these inﬂam-
matory processes, are not well understood. Nuclear hor-
mone receptors are known to regulate inﬂammation through
gene transcription and represent key candidates [15]. There
is evidence for a role of glucocorticoids acting through
glucocorticoid receptors (GRs), archetypal nuclear recep-
tors, in the pathophysiology of PD. For instance, basal
plasma cortisol levels are signiﬁcantly elevated in PD
patients, suggesting a deregulated hypothalamo-pituitary-
adrenal axis, which is known to affect GR activity [16].
Fig. 1 Tamoxifen-dependent Cre expression, recombination and
determination of GR deletion in GRCx30CreERT2 mice. a Representative
panels showing Cre immunohistochemistry in GRCx30CreERT2 mice
injected with either vehicle or tamoxifen, in cortex (cx), striatum,
septum, substantia nigra (SN) and hippocampus. The small squares in
tamoxifen-positive images are magniﬁed in upper panels to show Cre
recombinase. Scale bar, 200 μm. b Representative images showing
mTomato (red) staining after vehicle injection and appearance of
mGFP expression in astrocytes of striatum, substantia nigra (SN) and
hippocampus after tamoxifen injections in Cx30CreERT2:mT/mG
mice. Scale bar, 100 μm. c Representative images showing double
labeling of GR (red) and S100β (green) in cortex of GRloxp/loxP controls
and GRCx30CreERT2 mice injected with tamoxifen. Scale bar, 5 μm. d, e
Quantiﬁcation of the percentage of S100β + astrocytes co-labeled with
GR and (d) and NeuN+ neurons expressing GR (e) in cortex (Cx),
striatum (ST) and substantia nigra (SN) of controls and GRCx30CreERT2
mutant mice injected with tamoxifen. *p < 0.05; **p < 0.01, mutant vs
control. Error bars represent SEM. n= 4–5/group
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Therefore immune responses under GR control may also be
deregulated in PD. We previously showed that total GR
levels are reduced in SN of post-mortem PD, as well
microglial/macrophagic GR plays a crucial role in the sur-
vival of DNs following treatment with Parkinsonian neu-
rotoxin MPTP (which induces selective degeneration of
DNs by targeting DNs leading to gliosis) [17].
To understand the role of GR in astrocytes during
dopamine neurodegeneration, we inactivated GR gene in
protoplasmic astrocytes by crossing BAC-Tg (Cx30-
CreERT2) mice [18] with GR loxP/loxP mice [19].
We show that loss of astrocyte GR signaling increases
the expression of speciﬁc inﬂammatory genes in SN,
induces microglial activation and enhances degeneration
of DNs following MPTP treatment. Importantly, connexin-
mediated hemichannel activity plays a crucial role in
these actions of astrocytic GR. Finally, analysis of
astrocytes in SN of PD postmortem brain samples revealed a
signiﬁcant decrease in number of astrocytes expressing
GR suggesting, together with animal data, that compromised
GR signaling most likely contributes to neurodegeneration
in PD.
Results
Evaluation of Cre expression and recombination
efﬁciency for GR speciﬁcally in astrocytes of
GRCx30CreERT2 mice
Widespread Cre expression evident in the cortex, septum,
SN, striatum and hippocampus was observed only in
GRCx30CreERT2 mutant mice injected with tamoxifen but not
with vehicle (Fig. 1a). The tamoxifen-induced Cre recom-
bination was veriﬁed in mT/mGCx30CreERT2 reporter mice,
where Cre-mediated excision induces expression of GFP.
GFP+ cells were found in all brain regions examined
(Fig. 1b). The efﬁcacy of GR inactivation by Cre recom-
bination in the astrocytes of GRCx30CreERT2 mutants was
determined by co-labeling of GR and S100β with
Fig. 2 Loss of astrocytic GR exacerbates MPTP-induced degeneration
of DNs. a TH immunohistochemistry in SN of control and
GRCx30CreERT2 mice 7 days after acute MPTP intoxication. Scale bar,
100 μm. b Quantiﬁcation of TH+ neurons in SN 3 and 7 days after
MPTP treatment, showing a signiﬁcant reduction in GRCx30CreERT2
mutants compared with controls. #p < 0.05; ##p < 0.01 saline vs
MPTP; *p < 0.05; **p < 0.01 controls vs mutants, error bars represent
SEM, post-hoc Bonferroni/Dunn test, n= 5 mice/group. c Optical
density of TH immunoreactivity in striatum normalized to saline-
treated mice 3 days after MPTP intoxication. MPTP decreases
TH density more strongly in mutants compared to control animals
indicative of further loss of DN nerve terminals. #p < 0.05 saline vs
MPTP. **p < 0.01 controls vs mutants, error bars represent SEM.
n= 5 mice/group. d Percentage of GFAP+ astrocytes expressing GR
in striatum (ST) and SN in control and mutant GRCx30CreERT2 mice
3 days following MPTP intoxication. *p < 0.05 controls vs mutants,
n= 5 mice/group
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quantiﬁcation of GR+ astrocytes in control and mutant
mice. In controls, on average 75% of S100β-positive
astrocytes expressed GR compared to only 39% in the
mutants. The Cre recombination efﬁciency varied between
51% in the cortex, 49% in the striatum and 44% in the SN
(Fig. 1c, d). These values are similar to those reported in
Cx30 mice using a different reporter [18] and in GFAP-
CreERT2 conditional astrocyte mice [20]. The Cre
Fig. 3 Analyses of glial
reactivity resulting from MPTP
intoxication in control and
astrocytic GR mutant mice. a
Immunohistochemical staining
with anti–Iba-1 antibody in SN
3 days after MPTP treatment
shows increased microglial
activation in the GRCx30CreERT2
mutants. Scale bar, 50 μm. b, c
Quantiﬁcation of surface area (s.
a) and density (right) of Iba-1+
microglia in SN (b) and striatum
(ST) (c) of controls mice and
GRCx30CreERT2 mutants 3 and
7 days after saline or MPTP
injection. **p < 0.01; *p < 0,05
controls vs mutants, post-hoc
Bonferroni/Dunn test. #p < 0.05;
##p < 0.01; ##p < 0.01saline vs
MPTP. d, e Quantiﬁcation of
surface area (s.a) and density
(right) of GFAP+ astrocytes in
SN (d) and striatum (e) in
control mice and GRCx30CreERT2
mutants 3 and 7 days after saline
or MPTP injection. #p <
0.05 saline vs MPTP. In all,
error bars represent SEM. n= 5
mice/group
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recombination in GRCx30CreERT2 mutant mice was speciﬁc to
astrocytes as GR expression in NeuN+ neurons of cortex,
striatum and SN was unaffected (Fig. 1e).
Loss of astrocytic GR increases susceptibility of
substantia nigra DNs to MPTP toxicity
To study the contribution of astrocytic GR to neurodegen-
eration in PD, tamoxifen pre-treated control and
GRCx30CreERT2 mutant mice were injected with either saline
or MPTP. DNs in SN were quantiﬁed following immuno-
histochemistry (IHC) for tyrosine hydroxylase (TH). MPTP
triggered DN loss of around 20% in controls at 3 days and
41% at 7 days whereas in the mutants the DN loss was
signiﬁcantly more robust averaging 30 and 62% at 3 and
7 days respectively (Fig. 2a, b). This ﬁnding indicated that
astrocytic GR protects DNs against MPTP-mediated
nigrostriatal injury. This was further supported by striatal
TH IHC of dopaminergic nerve terminals at 3 days. Optical
density analysis showed larger decrease in mutants (51%)
compared to controls (34%) after MPTP treatment (Fig. 2c).
Previously, we reported increased density of GR-positive
microglial nuclei upon a surge in GC levels during MPTP
intoxication [17]. We quantiﬁed GR+GFAP+ astrocytes
in the striatum and SN 3 days following MPTP treatment.
The results showed 87% of GFAP+ astrocytes of SN and
Fig. 4 Analysis of inﬂammatory mediators in SN following MPTP
intoxication displaying differential changes in astrocytic GR mutants
compared to controls a Expression levels of selected inﬂammatory
genes measured by RT-qPCR in SN of GRCx30CreERT2 mutant mice
compared to control mice 18 and 42 h after saline or MPTP injection.
HPRT was used as internal control *p < 0.05 controls vs mutants; #p <
0.05 saline vs MPTP injected; error bars are SEM. n= 5 mice/group. b
Protein level of TNF-α in SN of control and GRCx30CreERT2 mutant
mice 3 days after saline or acute MPTP injections. ##p < 0.02 saline vs
MPTP injected, *p < 0.05 controls vs mutants MPTP. Error bars
represent SEM. n= 4 mice/group
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striatum expressed GR in controls whereas in mutants only
33% of GFAP+ astrocytes showed GR labeling, indicating
a Cre recombination of 62% (Fig. 2d).
Microglial but not astrocyte reactivity is augmented
in GRCx30CreERT2 mutant mice following MPTP
intoxication
Acute MPTP intoxication induces glial reactivity in striatum
and SN, thus we analyzed the cell density and the surface
area (indicative of hypertrophy) of Iba-1+ and GFAP+
cells in these regions. MPTP intoxication in SN of control
mice caused a transient increase (40%) in microglial surface
area at 3 days compared to saline-injected mice, thereafter
decreasing to 18% at 7 days. In the astrocytic GR mutant
SN, this increase was stronger (66%) at 3 days and
remained elevated at 7 days (63%) (Figs. 3a, b). In the
striatum of control mice, there was no change in microglial
surface area after MPTP treatment whereas in the mutants a
40% increase was observed at 3 days and 105% increase at
7 days. The microglial density increased at 3 days in SN and
striatum following MPTP intoxication regardless of the
genotype. Notably, at 7 days, the increase remained sig-
niﬁcant in the striatum of MPTP-treated mutants compared
to saline treatment (Fig. 3c). On the other hand, GFAP+
astrocyte cell density and hypertrophy were similar in
control and mutant mice following MPTP treatment
(Figs. 3d, e).
Proﬁle of changes in gene expression in SN of
astrocytic GR mutants following MPTP-induced
injury
GR regulates transcription of both pro- and anti-
inﬂammatory genes [21–24]. The elevated microglial reac-
tivity in GRCx30CreERT2 mutants prompted us to analyze the
expression of GR-regulated inﬂammatory genes. In the SN
of control and mutant mice injected either with saline or
MPTP, RT-qPCR analysis at 18 and 42 h showed stronger
increases in 3 pro-inﬂammatory genes in mutants compared
to controls after MPTP: a) TNF-α level was higher by 4.7
fold at 18 h and remained signiﬁcantly elevated at 42 h
(Fig. 4a). Accordingly the TNFα protein level in the SN,
3 days following MPTP intoxication, was 2.5 fold higher in
mutants (Fig. 4b), b) ICAM-1 level was 1.4 fold higher and
c) IL-1β remained high at 42 h.
MCP-1 (CCL-2) was signiﬁcantly high at 18 h regardless
of the genotype (Fig. 4a). MPTP likely stimulates IL-6
signaling as IL-6R expression was increased in controls
(Fig. 4a) whereas IL-6 was down regulated in mutants
compared to controls. MKP-1 (mitogen-activated protein
kinase phosphatase 1) whose expression is stimulated by
GR was upregulated in controls and not mutants (Fig. 4a),
suggesting GR regulation of p38 kinase activity through
MKP-1 expression [25].
Gene expression of other functional categories was also
analyzed (Fig. S1). There was no change in glutamine
synthetase or GLT-1 expression in either controls or mutants
suggesting that MPTP treatment and GR in midbrain
astrocytes do not inﬂuence glutamate regulation. Interest-
ingly, in MPTP intoxicated mutants, the expression of
APOE was reduced whereas Cyp27A1 (sterol 27-hydro-
xylase) increased indicating cholesterol metabolism is
modulated by decreased GR activity in astrocytes. We also
analyzed mRNA levels of the enzymes involved in glu-
tathione (γ-glutamylcysteinylglycine or GSH) biosynthesis:
principally catalytic subunit of glutamate-cysteine ligase (γ-
glutamylcysteine synthetase) (GCLC), its modulatory sub-
unit (GCLM) and glutathione reductase. The results showed
a decrease only in the GCLM level 42 h after MPTP
administration (Fig. S1).
Role of GR in regulating Cx30 and Cx43 expression
and astrocyte hemichannel activity
TNF-α and IL-1β induce opening of astrocytic hemi-
channels composed of connexin-43 (Cx43) [26, 27]. To
examine the role of GR in Cx functions, we ﬁrst analyzed
mRNA and protein levels of two major astrocytic Cxs:
Cx30 and Cx43 [28] in the SN of control and GRCx30creERT2
mutant mice after MPTP treatment. RT-qPCR analysis
showed a strong increase of Cx43 mRNA levels in mutants
at 42 h compared to controls (Fig. S2A) with no change in
Cx30 mRNA levels (Fig. S2B). Protein levels of Cx43 and
Cx30 in SN were higher in saline-injected mutants indi-
cating that ablation of astrocytic GR enhances the basal
levels of these proteins. MPTP intoxication augmented
Cx30 levels in control SN, however in mutants the Cx
levels were reduced (Fig. S2C). Pro-inﬂammatory cytokines
and inﬂammation-activated JNK pathway were reported to
decrease Cx levels in astrocyte cultures [26, 29, 30].
Phosphorylated JNK levels were increased by two-fold in
the mutants (Fig. S2D), suggesting that this pathway may be
involved in degrading Cx proteins in the mutants.
To examine the impact of GR and MPTP on Cx function,
we assessed hemichannel activity by measuring ethidium
bromide (EtBr) dye uptake [31] in the nuclei of SN astro-
cytes of control/mutant midbrain slices, either untreated
(ACSF oxygenated medium) or treated with 50 μM MPP+
(an active metabolite of MPTP). EtBr ﬂuorescent signal in
the nuclei of GFAP+ astrocytes (Fig. 5a) in SN (control
n= 14 slices from 3 animals, mutant n= 19 slices from 4
animals) was quantiﬁed. The EtBr uptake was completely
inhibited by the general connexin channel blocker, carbe-
noxolone. Absence of EtBr ﬂuorescence with non-permeant
EtBr homodimer further conﬁrmed that EtBr uptake
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reﬂected hemichannel activity (Fig. 5a). Hemichannel
activity increased in SN astrocytes of both control and
mutant slices following MPP+ treatment (Fig. 5b).
Importantly, two-fold increase of EtBr uptake in mutant
MPP+-treated slices was observed compared to control
slices (Fig. 5b).
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Cx43 hemichannels are activated by an elevation of
cytosolic calcium concentration [Ca2+]i [32, 33]. The
impact of MPP+ and GR deﬁciency on [Ca2+]i in SN
astrocytes was analyzed using the calcium indicator Fluo-4
AM preferentially taken up by astrocytes. The speciﬁcity of
uptake was conﬁrmed by co-localization of Fluo-4 with
sulforhodamine 101 [34] (Fig. 5c). Quantiﬁcation of Fluo-4
ﬂuorescence intensity in astrocytes after MPP+ treatment
showed a signiﬁcant increase of [Ca2+]i in GR-inactivated
SN astrocytes compared to a small non-signiﬁcant increase
(p= 0.07) in controls (Fig. 5d).
In vivo Cx43 hemichannel activity is increased due
to GR loss from astrocytes and underlies the
enhnaced dopamine neurodegeneration
To show that Cx hemichannel activity observed in
MPP+ -treated midbrain slices also occurs in vivo, EtBr
experiments were performed on ex in vivo midbrain slices
with always, in parallel, control and GRCx30creERT mutant
mice injected with MPTP, sacriﬁced after 3 days (Fig. 6a).
EtBr ﬂuorescence in astrocytes was quantiﬁed in mutants
relative to controls. In agreement with MPP+ results, a
signiﬁcant increase (61%) in EtBr uptake was observed in
GR-inactivated SN astrocytes (Fig. 6b). Treatment of slices
with Gap26 mimetic peptide, a Cx43 hemichannel inhibitor
[32], signiﬁcantly decreased EtBr uptake in midbrain slices
from both control and mutant mice. These results indicate
that GR regulates Cx43 hemichannel activity following
MPTP treatment.
The effects of astrocytic GR on Cx hemichannels led us
to investigate the speciﬁc involvement of Cx43 hemi-
channels in MPTP-Parkinsonian model. TAT-Gap19 pep-
tide, which speciﬁcally inhibits Cx43 hemichannels without
inhibiting Cx43 gap junction communication or Panx1
channels, was used [35]. The peptide completely reversed
MPP+ -induced EtBr uptake in SN astrocytes of control and
mutant midbrain slices indicating the speciﬁc role of Cx43
hemichannels (Figs. 7a, b).
To show the role of Cx43 hemichannel activity in DN
degeneration, we injected mice with TAT-Gap19 peptide
(23 mg/kg), which crosses the blood brain barrier [35]. DNs
in SN were quantiﬁed 3 days after saline or MPTP with or
without TAT-Gap19 treatment. At this time point, TAT-
Gap19 had no evident effect on survival of DNs in controls,
however it completely prevented the additional loss of DNs
in mutants (Fig. 7c). Moreover, microglial hypertrophy in
SN and striatum decreased in TAT-Gap19 treated
GRCx30CreERT2 mutant mice (Fig. 7d). As hemichannel
activity was observed in controls (see Fig. 5b), TAT-Gap19
peptide treatment in C57Bl/6 mice injected with MPTP was
examined after a protracted time period of 7 days when 41%
DN loss is observed (see Fig. 2b). TAT-Gap19 peptide
reduced the loss of DNs in MPTP treated GR-intact animals
(Fig. 7e). Overall these results indicate that block of Cx43
impacts microglial activation and DN loss in MPTP-
Parkinsonian mice.
GFAP and GR labeling reveals reduction in
astrocytes with nuclear GR expression in SN of PD
patients compared to control subjects
To examine whether astrocytic GRs are affected in PD, we
undertook double-immunoﬂuorescence analysis of GFAP
and GR in the SN of aged-matched controls and PD patients
showing Lewy body pathology in the brain stem. GFAP
staining of parafﬁn sections revealed ﬁne morphological
features of astrocytes (Fig. 8a) and strikingly swollen var-
icosities of astrocytes processes were observed in some
ﬁelds of SN in PD sections (Fig. 8b). Quantiﬁcation of
hypertrophied GFAP+ astrocytes, found both in the control
and PD samples, (Fig. S3) revealed 29 ± 8/mm2 and 60 ± 3/
mm2 respectively (p < 0.02); however in PD not all ﬁelds
had high numbers of hypertrophied astrocytes (Fig. S3,
bottom panel).
GR was co-localized within Hoechst labeled nucleus of
GFAP+ astrocytes, however there were GFAP+ astrocytes
without GR in both control and PD samples (Fig. 8c).
Quantiﬁcation revealed 43.9 ± 4.6% of GFAP+ astrocytes
with nuclear GR staining in control samples compared to
16.4 ± 3.4% for PD samples indicating that number of
astrocytes with nuclear GR expression is signiﬁcantly
reduced in PD patients. GR expression was absent in 41.7 ±
3.4% of astrocytes in control samples compared to 56.8 ±
1.2% in PD samples implying that during PD pathology
signiﬁcantly more astrocytes have no GR (Fig. 8d). Taken
together, these ﬁndings suggest that GR transcription reg-
ulation is likely compromised in PD patients.
Fig. 5 EtBr uptake and Fluo-4 ﬂuorescence in astrocytes of midbrain
slices treated acutely with MPP+ show both increased hemichannel
activity and intracellular calcium alterations in astrocytes devoid of
GR. a Representative ﬂuorescence images showing GFAP+ astrocytes
(green) and EtBr uptake (red) in acute SN slices prepared from control
and GRCx30CreERT2 mutant mice under control conditions (ACSF), after
2 h of treatment with MPP+ (50 μM) alone and in presence of either
the general connexin channel blocker carbenoxolone (200 μM) or EtBr
homodimer. Scale bar, 5 μm. b Quantiﬁcation of EtBr ﬂuorescence
intensity in GFAP+ astrocytes normalized to control ACSF condition
(taken as 100) in GFAP+ astrocytes of control and GRCx30CreERT2
mutant mice after 2 h of MPP+ treatment. #p < 0.05 MPP+ vs ACSF,
**p < 0.01 control vs mutant mice, error bars represent SEM. n= 3–4
mice/group. c Representative ﬂuorescence images of Fluo-4 ﬂuores-
cence in astrocytes, which was veriﬁed by sulphorhodamine (SR101)
(upper panel) and after MPP+ treatment in control and mutant SN
slices. d The Fluo-4 ﬂuorescence, indicative of [Ca2+]i was quantiﬁed
in control and mutant MPP+midbrain slices. ##p < 0.02 mutant ACSF
vs mutant MPP+, error bars represent SEM, n= 3 mice/group
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Discussion
In this study, we dissected how GR signaling in astrocytes
protects DNs in SN and dopaminergic nerve terminals in the
striatum during degeneration of DNs triggered by MPTP.
We also examined whether GR expression is modiﬁed in
post-mortem SN of PD patients. Our present results support
the notion that impaired GR activity can deregulate astro-
cyte functions during neurodegeneration, contributing to
chronic inﬂammation and DN loss.
Absence of astrocytic GR increases DN loss,
microglial reactivity and expression of inﬂammatory
mediators
Increased DN loss in GRCx30creERT2 mutant mice after
MPTP-mediated injury paralleled stronger microglial
reactivity and expression of pro-inﬂammatory mediators.
Thus elevated TNF-α as well as pro-IL-1β and I-CAM1
mRNA levels were observed in mutant SN after MPTP
treatment. The high levels of TNF-α and IL-1β in mutants
could potentially trigger further DN loss. The augmented
hypertrophy of microglia also suggests that GR in
astrocytes dampens microglial reactivity during dopamine
neurodegeneration. Reactive astrocytes have been shown to
exert both stimulatory and inhibitory effects on microglial
activation. Thus, for example, in vitro TGF-β secreted
from astrocytes was shown to curb microglial production of
TNF-α and reactive oxygen species [36] whereas evidence
from in vivo PD animal models and in vitro astrocyte-
microglia cultures indicates that IL-1β, TNF-α, I-CAM1 or
ATP released from astrocytes can enhance microglial
activation [37, 38]. Concerning the latter, evidence from
in vivo PD animal models and in vitro astrocyte-microglia
cultures indicates that these factors released from
astrocytes can enhance microglial reactivity through their
respective microglial receptors [37, 38]. ICAM-1 positive
astrocytes surrounded by microglia expressing LFA-1
(lymphocyte function-associated antigen) receptors have
been detected in areas of intense DN loss and extracellular
accumulated neuromelanin in the post-mortem SN of PD
patients [11]. Other well-known GR targets genes such as
iNOS or CCL-2 were not modulated in mutant mice, in
contrast to our previous ﬁndings of their increased
levels after inactivation of GR microglia [17, 39]. This
indicates cell-speciﬁc impact of GR signaling on gene
expression.
GR stimulates directly transcription of anti-inﬂammatory
genes such as MKP-1 whose protein product depho-
sphorylates p38 kinase and thereby prevents stimulation of
JNK and AP-1 transcription. The increased MKP-1
expression in MPTP-treated control but not mutant mice
suggests that MKP-1 levels are blunted by the absence of
GR in astrocytes. A decrease in MKP-1 is known to lead to
increased phosphoJNK levels as seen in SN of astrocytic
mutant mice after MPTP treatment. High levels of phos-
phoJNK and pro-inﬂammatory cytokines may also explain a
decrease in Cx30 and Cx43 protein levels in SN of astro-
cytic GR mutants, as shown previously [26, 30]. However,
Cx levels in astrocytes are up or down regulated by many
factors such as neuronal activity or type and duration of
insult [40, 41].
Fig. 6 In vivo astrocytic GR regulates Cx43 hemichannel activity
following MPTP intoxication. a Representative ﬂuorescence images of
acute midbrain slices maintained in ACSF, derived from control and
GRCx30CreERT2 mutant mice sacriﬁced 3 days after MPTP intoxication
showing GFAP+ astrocytes (green) and EtBr uptake (in red). Scale
bar, 5 μm. b (Left) Quantiﬁcation of EtBr ﬂuorescence intensity in
GFAP+ astrocytes of midbrain slices prepared from GR control and
mutant mice 3 days after MPTP intoxication. The change in MPTP-
mutant mice is represented relative to MPTP-control mice. *p < 0.05
control vs mutant MPTP, n= 4 mice/group. (Right) Quantiﬁcation of
EtBr ﬂuorescence intensity after 15 min of pretreatment with 200μM
Gap26 mimetic peptide, an inhibitor of Cx 43 hemichannels in SN
slices from controls and mutant mice sacriﬁced 3 days after MPTP.
The results are represented relative to presence or absence of Gap26 in
control or mutant slices. #p < 0.05, Gap26+MPTP vs MPTP, *p <
0.05 control vs mutant MPTP, error bars represent SEM, n= 4/group
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Fig. 7 Speciﬁc inhibition of Cx43 hemichannel activity by TAT-
Gap19 protects DNs and reduces microglial reactivity, particularly in
astrocytic GR mutants, in response to MPTP neurotoxicity. a Repre-
sentative ﬂuorescence images of midbrain slices derived from control
and GRCx30CreERT2 mutant mice showing GFAP+ astrocytes (green)
and EtBr uptake (red) after 2 h of treatment with MPP+ (50 μM), and
after 30 min of pre-treatment with TAT-Gap19 (300 µM). Scale bar, 5
μm. b Quantitative data of experiments as illustrated in panel a
showing almost complete inhibition of EtBr uptake both in control and
mutant midbrain slices. # p < 0.05 control MPP+ vs controls MPP+
TAT-Gap19; ##p < 0.01 mutant MPP+ vs mutant MPP+ TAT-Gap19.
*p < 0.05 control vs mutant slices in the presence of MPP+, error bars
represent SEM, n= 5–6/group. c Quantiﬁcation of TH+ neurons in
SN 3 days after saline or MPTP intoxication, with or without TAT-
Gap19 injections. In vivo TAT-Gap19 treatment protects SN DN
degeneration in GR astrocyte mutant mice. #p < 0.05 saline vs MPTP;
*p < 0.05 mutant MPTP vs mutant MPTP TAT-Gap19, error bars
represent SEM, n= 5 mice/group. d Iba1+microglial surface area (s.
a) in SN and striatum (ST) of control and astrocyte GR mutant mice
after MPTP with or without TAT-Gap19 injections. TAT-Gap19
inhibits microglial hypertrophy in GR astrocyte mutant animals. #p <
0.05 MPTP vs MPTP TAT-Gap19 in mutant mice. e Quantiﬁcation of
TH+ neurons 7 days after MPTP intoxication in the SN of C57BL/6
mice injected with saline (sal), MPTP with ot without TAT-Gap19. *p
< 0.05 MPTP+ TAT-Gap19 vs MPTP in C57BL/6 mice, error bars
represent SEM, n= 4–5 mice/group
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Control of Cx43 hemichannel activity by astrocytic
GR and its impact on dopamine neurodegeneration
The increased pro-inﬂammatory mediators observed in SN
of GRCx30creERT mutant mice could potentially act to induce
not only DN loss and microglial reactivity, but also play a
role in opening astrocyte Cx hemichannels. In our previous
study, TNF-α and IL-1β from hippocampal astrocytes
activated Cx43 hemichannels without affecting their
gap-junction communication [27]. In astrocytes of control
MPP+-treated midbrain slices, we found Cx hemichannel
activity upregulated, as assessed by EtBr uptake, which was
increased further and signiﬁcantly in GR mutant MPP+
slices. This result was then recapitulated in vivo in acute
slices prepared from astrocytic GR mutant and control mice
injected with MPTP.
To show the speciﬁc involvement of Cx43 hemichannels
in astrocytes of SN after MPP+ or MPTP treatment, we
took advantage of speciﬁc properties of Gap26 and TAT-
Gap19 Cx inhibitory peptides. Gap26 reproduces a
sequence of the ﬁrst extracellular loop which results in the
blocking of hemichannels within minutes [42], while Gap19
represents a short sequence present in the L2 domain of the
intracellular cytoplasmic loop of Cx43 [43]. Its speciﬁcity
relates to distinct outcomes of interactions between the C-
terminal tail with the intracellular loop of Cx43 [44]. Gap19
binding to the C-terminal tail results in inhibition of
hemichannel opening triggered by, for example, intracel-
lular Ca2+ elevation in the range of 500 nM or below [33,
44]. Our results showed that both these peptides inhibited
almost completely the hemichannel activity in SN astro-
cytes of mice intoxicated with MPTP. The opening of Cx43
hemichannels is also associated with increased intracellular
Ca2+ [33, 45]. We observed a rise in [Ca2+]I in SN astro-
cytes of mutant slices treated with MPP+which suggests
that together with TNF-α and Il-1β, signiﬁcant Cx43
hemichannel opening may produce intercellular Ca2+ wave
propagation thereby recruiting other reactive astrocytes and
spreading inﬂammation and neurodegeneration-associated
signals.
Importantly, we found in astrocytic GR mutant mice,
Cx43 hemichannel activity impacts directly DN loss and
microglial reactivity. Thus TAT-Gap19 co-treatment with
MPTP intoxication in astrocytic GR mutant mice reversed
Fig. 8 GFAP astrocytes analyzed for GR expression in SN post-
mortem from control subjects and PD patients. a, b Representative
ﬂuorescent images of GFAP-labeled astrocytes in SN of parafﬁn
sections from control subjects and PD patients. Arrowheads and
asterisks in (a) depict two similar astrocytes in control and PD,
however they are hypertrophied in PD. In (b) note swollen varicosities
of astrocyte processes in PD compared to control. Scale bar, 10 μm. c
3D confocal images of GR localization in nucleus or its absence in
nucleus in GFAP- labeled astrocytes. Scale bar, 2 μm. d Quantiﬁcation
of GR localization in nucleus or its absence in astrocytes, represented
as % of total number astrocytes analyzed. **p < 0.01 control subjects
(n= 6) versus PD patients (n= 5), error bars represent SEM
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both increased DN loss as well as the microglial reactivity.
In wild-type mice, we observed a partial protective effect of
around 20% with TAT-Gap19, which likely reﬂects the
lower Cx43 hemichannel activity in the presence of GR.
Thus astrocytic GR regulates Cx43 hemichannel activity
during MPTP-induced Parkinsonism, which in turn affects
dopamine neurodegeneration.
Astrocytes changes and astrocyte GR signaling in SN
of PD patients
Our results with GFAP labeling of astrocytes in sections
from autopsied brains of control subjects and PD patients
show greater hypertrophied astrocytes as well as swollen
varicosities in astrocyte processes in some confocal ﬁelds of
SN in PD. However, further detailed analyses in SN, for
example, astrocytes around blood vessels versus dying
neurons, should shed insights into their functional altera-
tions in PD pathology. In PD patients, the number of
astrocytes showing GR in the nucleus is drastically reduced
whereas the number without GR is signiﬁcantly increased.
This overall GR decrease suggests that astrocytic GR
functions in PD are compromised which would lead to pro-
inﬂammatory state and neurodegeneration.
Impaired GR activity in immune-competent cells has
been observed in diseases ranging from chronic obstructive
lung disease, asthma, diabetes and cancer [46–48]. High
cortisol levels and impaired immune functions are also
features of aging and they likely play into neurodegenera-
tion in PD as aging is regarded as an important risk factor in
PD [49]. The reduced GR activity in astrocytes in our
mouse model leads to increased levels of potent pro-
inﬂammatory cytokines as well as microglial activation
where connexin hemichannels play a crucial role. Together
with ﬁndings in human post mortem SN, it is likely that in
PD pathology progressive deregulation of astrocyte func-
tions by GR has an effect on spreading and amplifying
neuroinﬂammation contributing to neuronal degeneration.
Materials and Methods
Reagents and antibodies
MPTP, tamoxifen, MPP+, normal goat serum (NGS), dia-
minobenzidine, H2O2, carbenoxolone and ethidium bromide
were purchased from Sigma-Aldrich. Vectastain Avidin-
biotin peroxidase ABC kit, Vectashield and Vectamount
mounting media were purchased from Vector. RNeasy
Lipid Tissue Mini Kit was purchased from Qiagen. Super-
script III reverse transcriptase kit and mouse ELISA TNF-α
kit were purchased from InVitrogen. Iba-1 antibody was
obtained from Wako. S100-beta and GFAP antibodies were
purchased from Sigma-Aldrich; tyrosine hydroxylase (TH)
and NeuN antibodies from Merck Millipore; GR antibodies
from Santa Cruz (M20) and AbCam. Secondary biotiny-
lated antibodies were purchased from Vector, whereas
ﬂuorescent secondary antibodies, anti-mouse Alexa 488,
anti-rabbit Cy3 and anti-rabbit Alexa 633 were purchased
from InVitrogen. Cx43-mimetic peptide Gap26 and TAT-
Gap19 were obtained from Pepnome Inc. and synthesized at
>95% purity.
Mice
All the animals were bred and raised under a 12/12 h light/
dark cycle, temperature was 22 ± 1 °C and humidity 60 ±
5%. Food and water were supplied ad libitum. Experiments
were performed in accordance with French (Ministère de
l’Agriculture et de la Forêt, 87848) and European Com-
munity council directives of 2013 (2010/63/EU) guidelines
for the care of laboratory animals and approved by Uni-
versity Pierre et Marie Curie and ICM committees for ani-
mal care and use. All efforts were undertaken to minimize
suffering and minimal numbers of animals were used.
Generation of mice with conditional inactivation of GR
(Nr3c1) gene in astrocytes
GRCx30CreERT2 mice were produced by crossing C57BL/6
mice harboring a conditional GR (Nr3c1) allele [19] with
mice expressing CreERT2 under control of the Cx30 pro-
moter Tg [(Gjb6-cre/ERT2)53-33Fwp; MGI: 4420273]
already bred on a C57BL/6 background [18]. Experiments
were performed on male GRloxP/loxP;Tg(Gjb6-cre/ERT2)
mice, thereafter denominated GRCx30creERT2 and their con-
trol littermates (GRloxP/loxP) mice, which were generated by
crossing GRCx30creERT2 males with GRloxP/loxP females. The
mice were genotyped for the presence of Cre transgene [18]
and GRloxP alleles by PCR of tail biopsies. Both control and
mutant mice were injected i.p. with 1 mg tamoxifen (solu-
bilized in 1:9 ethanol/sunﬂower oil followed by 10 min bath
sonication) twice daily for 5 consecutive days. The
experiments were undertaken 3 weeks after the last
tamoxifen injection to ensure the absence of GR protein and
of tamoxifen.
Generation of mT/mG Cx30C reERT2 for Cre recombinase
veriﬁcation in astrocytes
To verify Cre-mediated recombination, Tg(Gjb6-cre/ERT2)
mice were crossed with a global double-ﬂuorescent Cre
reporter mice (mT/mG) [50] expressing membrane-targeted
tandem dimer Tomato (mT) prior to Cre-mediated excision
and membrane-targeted green ﬂuorescent protein (mG) after
Cre excision (mT/mGCx30 creERT2 mice) under the control of
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Cx30 promoter. For Cre veriﬁcation, mutant mice were
injected either with tamoxifen or vehicle solution.
MPTP treatment
All experiments were performed on 3–5 months old male
mice. GRCx30creERT2 mutant mice and their control litter-
mates GRloxP/loxP were given four i.p. injections of 18 mg/kg
MPTP·HCl or the same volume of saline at 2 h intervals.
Mice were sacriﬁced at indicated time points after the last
injection.
TAT-Gap19 in vivo administration
To examine whether Cx43 is implicated in DN loss, TAT-
Gap19 Cx43 inhibitor peptide was injected i.p. in parallel
with MPTP at 23 mg/kg concentration in control and
GRCx30CreERT2 mutant mice, as well as C57BL/6 mice; total
of 4 injections at a 2 h interval, and once/day for further
2 days following MPTP intoxication. The mice were
sacriﬁced 3 or 7 days thereafter.
Tissue preparation and staining speciﬁcity
Mice were anesthetized with CO2 and perfused transcar-
dially with ice-cold 0.1 M sodium phosphate buffer (PBS)
followed by ice-cold 4% paraformaldehyde (PFA) in 0.1 M
sodium phosphate buffer. Brains were rapidly removed
from the skull, post-ﬁxed for 24 h in fresh 4% PFA/PBS
solution and serially cut as 30 µm thick coronal sections as
described [17]. The sections were stored in PBS containing
0.4% sodium azide at 4 °C until use.
Immunostaining
Immunohistochemistry protocols used were essentially as
described in Ros Bernal et al. [17] and Carrillo-de Sauvage
et al. [39]. Brieﬂy, SN, striatal and cortical sections at
180 µm interval were incubated with either rabbit poly-
clonal anti-Cre (1:1000), or rabbit polyclonal anti-Iba1
(1:750) or anti-GFAP (1:2000) or mouse monoclonal anti-
TH (1:1000) primary antibodies for 24 or 48 h at 4 °C with
constant shaking. Sections were incubated for 2 h at room
temperature with appropriate anti-mouse or anti-rabbit
biotinylated secondary antibodies (1:500). Antibody detec-
tion was performed with avidin-biotin peroxidase ABC
Vectastain kit according to manufacturer’s instructions and
using the chromogen diaminobenzidine (DAB) as perox-
idase substrate. Sections were mounted on super-frost plus
slides and dehydrated in graded ethanol series and xylene,
then cover-slipped using Vectamount.
For immunoﬂuorescence, primary antibodies used were
anti-Iba1 (1:750), anti-GFAP (1:2000), mouse monoclonal
anti-S100β (1/200), rabbit polyclonal anti-GR (1/750) and
mouse monoclonal anti-NeuN (1/500) antibodies. Appro-
priate secondary antibodies were anti-rabbit Cy3, anti-
mouse cy3, anti- mouse or rat Alexa 488 at 1/400 dilution.
After incubating PBS solution containing Hoechst (1/2000)
they were mounted using Vectashield for examination and
analysis by ﬂuorescence or confocal microscope.
Quantiﬁcation of immunostained sections
To calculate Cre recombination efﬁcacy, sequential images
from processed Z-stacks comprising four different ﬁelds
per section were obtained with Zeiss microscope (Axiovert
200M) ×40 objective, equipped with Apotome module. The
number of astrocytes double stained with S100β and GR, as
well as the numbers of neurons double labeled with NeuN
and GR were compared between control and GR astrocyte
mutant mice.
DN quantiﬁcation was performed stereologically as
previously described [17] on regularly spaced DAB sections
of mesencephalon covering the whole SN (from rostral pole
of the SN to the locus coeruleus) by bright-ﬁeld microscopy
using Nikon microscope ×20 objective equipped with a
semiautomatic stereology system (Mercator software;
Explora Nova VisioScan T4.18 system). The genotype of
mice was unknown to the investigator at the time of
quantiﬁcation. Surface area and number of activated Iba-1
positive microglia and GFAP-labeled astrocytes were
quantiﬁed from 5-6 ﬁelds chosen at random of each DAB
labeled SN section (×40 objective) and covering entire SN
and striatum of control and GR astrocyte mutant mice using
ImageJ software. The density of striatal dopaminergic
terminals was quantiﬁed based on optical density of TH-IR
in striatal sections from control and mutant mice using
MCIDTM Analysis system
RT–quantitative PCR (RT-qPCR)
Mice were euthanized 18 or 42 h after acute MPTP treat-
ment and their brains snap-frozen in isopentane at −25 °C.
The SN region was dissected by punch at −5 to −10 °C
under sterile conditions. Total RNA was prepared using the
lipid RNeasy Lipid Tissue Mini Kit. To ensure complete
DNA elimination, an on-column DNase step was per-
formed. The RNA integrity and concentration were quan-
tiﬁed based on optical density using the NanoDrop ND-
1000 spectrophotometer (Thermo Fisher Scientiﬁc). cDNA
synthesis was performed on 500 ng RNA, using the
Superscript III cDNA Reverse Transcriptase Kit. cDNA was
stored at −20 °C until use. qPCR experiments were carried
out on Roche Light Cycler 480-II (Roche Diagnostic) using
Syber Green master mix from Roche diagnostics. Samples
for RT-PCR were run in triplicate and contained 5 μl
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Sybergreen, 0.3 μl of each of the forward primer and reverse
primer (10 μM), and 3 μl RNase-free water. Quantiﬁcation
was achieved by the relative quantitation method, with
serial dilutions of cDNA to construct a linear standard curve
relating cycle threshold values to relative concentrations.
Gene expression data were normalized to the housekeeping
gene HPRT.
TNF-α ELISA
Control and mutant mice injected with MPTP were sacri-
ﬁced 48 h after the injections. Mice were decapitated, brains
extracted rapidly and snap-frozen in isopentane at −25 °C.
Brains were stored at −80 °C until further processing.
Punches of substantia nigra were obtained from frozen tis-
sue. SN samples were immersed in ice-cold lysis buffer
containing 50 mM Tris-HCl, 100 mM NaCl, 2 mM EDTA,
1% Triton X-100 and a 1% total protease inhibitor cocktail,
and sonicated for 10 s. The samples were centrifuged at
13000 rpm for 20 min at 4 °C and supernatants stored at
–80 °C. Levels of the TNF-α were analyzed by an ELISA
kit according to the manufacturer’s protocol. Total protein
concentrations were measured using the Bradford protein
assay.
Western blot analysis
Mice were euthanized 48 h after saline or acute MPTP
injections and their brains snap-frozen in isopentane. Pun-
ches of striatum and substantia nigra were lysed in 140 μl of
boiling SDS 2% (with complete Roche protease inhibitor
cocktail, orthovanadate 1 mM and glycerophosphate 10
mM) and then sonicated. 50 μg of protein samples were
loaded on Novex NuPage 4–12% Bis-Tris gradient gels
(Invitrogen). After transfer onto a PVDF membrane, the
blots were probed with Cx43 and Cx30 or phosphoJNK
primary antibodies. Blots were reincubated with GAPDH
antibody for loading control. After incubation with sec-
ondary peroxidase-conjugated antibodies (GE Healthcare)
diluted at 1:2000, signals were visualized by using the ECL
detection kit (GE Healthcare).
Hemichannel experiments
Acute SN slices
Acute coronal midbrain slices were prepared from 4-6
months old GRCx30CreERT2 and GRloxP/loxP mice. After
decapitation, brains were rapidly isolated and placed in ice-
cold slicing solution containing the following (in mM): 27
NaHCO3, 222 sucrose, 10 glucose, 2.6 KCl, 1.5 NaH2PO4,
0.5 CaCl2, 7 MgSO4 and 0.1 ascorbic acid; and
bubbled with 95% O2/5% CO2. Midbrain coronal brain
slices (300 μm) were cut using a vibratome (VT 1200;
Leica). Slices were transferred to a holding chamber at room
temperature and stabilized for 1 h in artiﬁcial CSF (ACSF)
containing the following (in mM): 125 NaCl, 2.5 KCl, 25
glucose, 25 NaHCO3, 1.25 NaH2PO4, 2 CaCl2, and 1
MgCl2, pH 7.4 and bubbled with 95% O2/5% CO2 at room
temperature in the presence of 2 mM Na pyruvate.
Dye uptake
Acute slices were either left untreated or incubated with
different concentrations (50, 100, 200 μM) of MPP+ for 1,
2 or 3 h in oxygenated (95% O2 and 5% CO2) ACSF, pH
7.4 in a chamber at room temperature. Thereafter the slices
were incubated with 5 μM ﬁnal concentration of ethidium
bromide for 10 min. After all treatments, slices were washed
×3 with ACSF and ﬁxed at 4 °C with 4% paraformaldehyde
for 1 h. 50 μM MPP+ treatment for 2 h was found to be
optimal as it induced hemichannel activity without causing
non-speciﬁc membrane permeabilization as visualized by
the lack of EtBr uptake. To verify for uptake via connexin
hemichannels, slices were incubated 15 min prior to as well
as during EtBr application with the general connexin
channel blocker carbenoxolone (CBX, 200 μM), EtBr
monomer (5 μM), mimetic blocking peptide Gap26
(200 μM) or TAT- Gap19 (300 μM).
Staining and image analysis
Slices were incubated with blocking solution (0.2% gelatin/
1% Triton X-100 in PBS) for 1 h. Primary antibodies, anti-
Iba1 (1/500) and anti-GFAP (1/500) were prepared in
blocking solution containing 10% NGS and incubated at 4 °
C overnight. The following day, slices were incubated with
appropriate secondary antibodies conjugated to Alexa 488
or Alexa 633 for 2 h, then washed and mounted with
Vectashield. Stacks of consecutive images at 0.5 μm inter-
vals were acquired sequentially with three lasers at 488 and
555 and 633 nm (40×) on a confocal laser-scanning Leica
microscope. Three ﬁelds were selected at random in SN per
slice. 10–12 Z-projections of serial optical sections (0.5 μm)
were then reconstructed with ImageJ software. Fluorescence
was quantiﬁed in arbitrary units with imageJ software. Dye
uptake ratio was calculated as the subtraction (F-F0)
between the ﬂuorescence F from cells and the background
ﬂuorescence F0 measured where no labeled cells were
detected.
To measure hemichannel activity in SN slices prepared
from control or GRCx30CreERT2 mutant mice injected i.p with
MPTP as above and sacriﬁced 3 days after, uptake of EtBr
in SN slices of the mutant mouse was calculated relative to
uptake in SN slices of the control mouse, processed at the
same time.
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Intracellular calcium measurements
Acute brain slices from control and GRCx30CreERT2 mutants
incubated in ACSF with 95% O2/5% CO2, were treated with
50 μM MPP+ for 2 h at room temperature. Slices were then
incubated for 45 min in dark at 37 °C in ACSF containing
calcium indicator Fluo-4AM (5 μM), a calcium indicator
which is preferentially loaded in astrocytes [51]. Astrocytes
were further identiﬁed by their ability to uptake the ﬂuor-
escent tracer sulforhodamine 101 (SR 101) [52]. After dye
loading, slices were thoroughly washed by 20 min incuba-
tion in ACSF solution (equilibrated with 95% O2 to 5%
CO2). They were placed on a coverslip coated with poly-
lysine. Fluo-4 and SR 101 were excited at respectively 488
nm and 587 nm. Stacks of images were rapidly acquired
through a water immersion objective on a SP5 confocal
microscope with multi-photon laser. Images were analyzed
with Image J software [45].
Human postmortem sections
The samples were obtained from brains collected in a Brain
Donation Program of the Brain Bank “NeuroCEB” run by a
consortium of Patients Associations that include ARSEP
(association for research on multiple sclerosis), CSC (cer-
ebellar ataxias), and France Parkinson. The signed consents
were either from the patients or their next of kin in their
name, in accordance with the French Bioethical Laws.
The mean age of control and PD subjects was 67.5 ± 6.8
and 76.6 ± 3.8 years respectively (mean ± SEM). Control
group comprised of 3 males and 3 females whereas PD
group consisted of 3 males and 2 females. 2–3 transversal
sections/brain covering dorsal-medial and ventral-lateral
areas of SN, (SN area identiﬁed in brain stem tissue by
exiting ﬁbers of 3rd cranial nerve), were used for immuno-
ﬂuorescence experiments. Immunoﬂuorescence of GR and
GFAP was carried out both with 10 μm parafﬁn sections
(n= 2 for both control subjects and PD) as well as 30 μm
fresh sections which were stored at −80 °C (n= 4 for
controls and 3 for PD). For each experiment, equal number
of control and PD sections were included for immunola-
beling. To delineate SN area, TH immunohistochemistry
was performed on adjacent sections. Surface area of SN
comprising TH+ dopamine neurons was measured using a
Nikon microscope (Eclipse, ×20 objective) equipped with a
semi-automatic stereology system (Mercator software;
Explora Nova VisioScan T4.18 system). The mean SN area
in control and in PD samples was 29.94 ± 3.8 mm2 and 29.8
± 4.0 mm2 per section, respectively. For GR and GFAP
expression, similar results were obtained for parafﬁn sec-
tions and fresh tissues and thus the data were pooled.
Parafﬁn-embedded sections were deparafﬁnated in a series
of xylene/alcohol solutions, and antigen retrieval was
achieved by heating the sections at 80 °C for 20 min in 10
mM sodium citrate buffer, pH 6.0. Cryostat fresh sections
were air-dried before ﬁxation with freshly prepared 4%
PFA/ PBS solution for 20 min. The sections were rinsed in
tris-buffered saline (TBS) solution containing 0.5% Triton
before blocking for 2 h in 2% goat serum/TBS-0.5% Triton.
They were incubated with rabbit polyclonal anti-GFAP
antibody (Sigma-1/200) and mouse anti-GR antibody
(AbCam-1/200) in 2% goat serum/TBS-0.5% Triton for 48
h at 4 °C. After washes in TBS-0.5% Triton, they were
incubated with secondary antibodies: Alexa goat anti-rabbit
488 and donkey anti-mouse Cy3, washed, stained with
Hoechst 33342 and mounted using vectashield.
For imaging, confocal laser-scanning Leica microscope
with 40 × objective was used to acquire sequentially stacks
of consecutive images at 2 μm intervals with 3 lasers at 488
nm (GFAP) and 555 nm (GR) and 633 nm (Hoechst). The
ﬂuorescence across one entire image was determined; a
threshold for positive staining was set for each channel and
same settings were used for all acquisitions. 7 ﬁelds (each
0.15 mm2) spanning SN were selected at random; in total
they constitute about 1/30 of total SN area of the section.
For 30 μm sections, images were reconstructed to
obtain 6–8 μm thickness images corresponding approxi-
mately to nuclear size, this to avoid overlapping of cells.
These images of astrocytes with Hoechst staining were
analyzed for GR localization and quantiﬁcation using
ImageJ software, ARIVIS software was used for 3D
reconstruction.
Statistical analysis
Data are expressed as mean ± SEM. Statistical analyses
were performed by using Mann-Whitney non-parametric
test and two-way ANOVA. Post hoc comparisons between
mutant and control groups were made using a Bonferroni/
Dunn test. Differences of p ≤ 0.05 were considered statisti-
cally signiﬁcant. Statistical analyses were carried out using
StatView 5.0 software.
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